关于“寻医问药”的报告
艾媒咨询｜2024年中国养生茶饮行业现状研究及消费者洞察报告
国民健康需求的升级、养生文化的盛行、国家政策的支持与法令法规的准允，为药食同源产业的蓬勃发展提供了有力保障，也为养生茶饮的市场扩容注入了强劲动力。养生茶饮作为健康食疗的一种，结合了拥有数千年的历史底蕴与广大的群众基础的传统中医养生文化，被赋予着“寓医于食”的温和而个性化的天然优势。随着现代生活节奏加快和健康观念普及，养生茶饮成为了健康生活的新宠。全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2024年中国养生茶饮行业现状研究及消费者洞察报告》数据显示，2023年中国养生茶饮市场规模为411.6亿元，同比增长27.3%；预计2028年将突破千亿元。超九成消费者在每月养生茶饮的消费支出上超过了50元，而消费者消费养生茶饮时最重视的因素为口感与口味，其比例为65.2%。在消费群体年轻化已成趋势、健康理念成消费升级新需求的大背景下，养生茶饮企业需加强产品创新与技术升级为产业提质升级，并扩宽渠道可能，同时努力开拓年轻化的健康消费市场，创新传承中医养生文化来迎合市场需求，方可扩大市场影响力，抓住赛道机遇。
The enhancement of national healthcare needs, the promotion of health culture, the backing of national policies and the enactment of laws and regulations provide a robust assurance for the dynamic growth of the pharmaceutical and food industry, as well as inject a powerful impetus for the market expansion of healthy herbal beverage industry. Healthy herbal beverage, as a form of nutritious diet, integrates traditional Chinese medicine health culture with millennia-old history and broad public support, and is endowed with the gentle and personalized natural advantages of "integrating medicine into food". With the accelerated pace of modern life and widespread adoption of health concepts, healthy herbal beverage has emerged as a new favorite in healthy living.According to the latest Research Report 2024 China Health Herbal Beverage Industry Status Research and Consumer Insight Report released by iiMedia Research, a third-party data mining and analysis institution of the global new economy industry, China's healthy herbal beverage market size is projected to reach 41.16 billion yuan by 2023, representing a 27.3% increase. It is expected to surpass 100 billion yuan by 2028. Over 90% consumers spend more than 50 yuan per month on healthy herbal beverages, with taste being cited as the most important factor at 65.2%. Against this backdrop where younger consumer groups are gaining prominence and wellness concepts are driving consumption upgrades, healthy herbal beverage companies need to bolster product innovation and technological advancement to enhance quality while expanding potential channels. Simultaneously they should strive to tap into the younger demographic's interest in wellness products through innovative approaches that uphold traditional Chinese medicine culture in order to meet market demand effectively expand their influence.-
-
-
艾媒咨询|2021年中国夜间用药年度观察报告
本报告涉及的案例/品牌/企业：美团买药，叮当快药
在众多社会服务中，夜间用药成为人们最关注的夜间社会服务之一，近年来，各地相关行政管理机构也陆续出台相关扶持政策，鼓励商家上线夜间送药平台、发展24小时药店，提供夜间送药服务，推动解决“夜间买药难”问题。近日，iiMedia Research(艾媒咨询)最新发布《2021年中国夜间用药年度观察报告》，基于2021年初至2021年末的监测数据，对中国夜间用药市场持续追踪。报告显示，年初有61.2%的用户夜间生病选择忍，而年底这一数字降至52.1%，据推算年末夜间用药受益群体新增约4000万人。报告指出，日渐成熟的中国外卖送药平台，成为解决夜间用药的重要参与者。通过一年的发展，在美团买药“小黄灯”计划等24小时药店惠民工程的推动下，线上24小时药店数量增加、夜间买药配送速度更快、服务保障更加成熟，用户知晓度有了较大提升，夜间买药难的问题得到有效缓解。
Among many social services，night medication has become one of the night social services that people pay most attention to. In recent years，relevant administrative agencies around the country have also successively issued relevant support policies to encourage businesses to launch night medication delivery platforms，develop 24-hour pharmacies，provide night medication delivery services， and promote the solution of the problem of "difficulty in buying drugs at night". Recently， iiMedia Research released the annual observation report on nighttime medication in China in 2021，which continuously tracks China's nighttime medication market based on the monitoring data from the beginning of 2021 to the end of 2021. The report shows that at the beginning of the year， 61.2% of users chose to tolerate illness at night，while at the end of the year，the figure fell to 52.1%. It is estimated that about 40 million people will benefit from night medication at the end of the year.The report points out that the increasingly mature Chinese takeout delivery platform has become an important participant in solving the problem of night medication. Through one year's development，driven by the 24-hour pharmacy benefit project such as the "small yellow light" plan of meituan drug purchase， the number of online 24-hour pharmacies has increased，the speed of drug purchase and distribution at night is faster，the service guarantee is more mature，the user awareness has been greatly improved，and the problem of difficult drug purchase at night has been effectively alleviated. -
艾媒咨询|2021年夜间用药行业研究报告
本报告研究涉及企业/品牌/案例：美团，京东到家，饿了么
国内人口基数增长以及人们对于健康管理意识的增强，使得夜间用药市场的需求度也保持在较高的水平。iiMedia Research(艾媒咨询)数据显示，约89.9%受访者表示近一年有过夜间生病或者家人朋友需要用药的经历，并且，群众对夜间用药种类的需求丰富，并且在夜间各个时段的急性疾病需求都普遍较高。为此，04年起政府已经倡导24小时药店以满足用户需求。但是研究发现，“晚上买药难”是夜间生病人士普遍提及的关键词，即时配送平台兴起或成解决夜间用药新机遇。
The growth of the domestic population base and the increase of people's awareness of health management have kept the demand for night medication in the market at a relatively high level. According to data from iiMedia Research, about 89.9% of the interviewees said that they have had the experience of getting sick at night or needing medication at night in the past year. Moreover, the masses have a rich demand for medication at night, and acute illnesses at various times during the night. Disease needs are generally high. For this reason, since 2004, the government has advocated 24-hour pharmacies to meet user needs. However, the study found that "difficult to buy medicine at night" is a key word commonly mentioned by people who are sick at night. The rise of instant delivery platforms may be a new opportunity to solve night medicine. -
艾媒咨询|2021年3-4月中国化妆品行业运行数据监测双月报
本报告研究涉及企业/品牌/案例：花西子，资生堂，华熙生物
数据显示，中国化妆品及洗护用品进出口金额均呈现大幅度增长状态，并未受到2020年新冠疫情较大的负面影响。2021年1-4月，中国化妆品及洗护用品进口数量为14.6万吨，出口数量为29.2万吨；2021年1-4月，中国化妆品及洗护用品进口金额为515.8亿元，出口金额为84.4亿元。随着国内经济全面复苏，中国化妆品的出口数量有明显的增加趋势，照此趋势，预计2021年全年中国化妆品及洗护用品进出口金额或将有新的高峰。
Data show that the import and export volume of cosmetics and toiletries in China has increased significantly, and has not been seriously affected by COVID-19 in 2020. From January to April in 2021, China's imports of cosmetics and toiletries were 146000 tons and exports were 292000 tons; From January to April 2021, China's imports of cosmetics and toiletries amounted to 51.58 billion yuan, and its exports amounted to 8.44 billion yuan. With the comprehensive recovery of domestic economy, the export volume of China's cosmetics has an obvious increasing trend. According to this trend, it is expected that the import and export amount of China's cosmetics and toiletries will reach a new peak in 2021. -
艾媒咨询|2021全球及中国大健康产业运行大数据及决策分析报告
本报告研究涉及企业/品牌/案例：阿里健康，联合丽格，恒瑞医药，白云山，平安好医生，111集团，新氧，药明巨诺，盘龙药业，先导药业，好大夫在线，优健康，春雨医生，丁香医生，微医
受到人口老龄化、居民患病比例增加等因素影响，国家医疗费用支出不断增加，属于刚性需求；同时，随着人们对健康标准的不断提高以及互联网医疗技术的发展，大健康产业会在相当长的时期内持续保持增长态势。数据显示，2020年中国的大健康产业营收规模超过7万亿元，预计2021年将达8万亿元，增幅达8.1%。其中，得益于大健康产业发展以及疫情期间医药需求增长，生物制药、医疗器械两大细分领域表现良好，成为2020年中国投资热度较高的新经济行业，投资项目金额分别为919亿元和273亿元。
Affected by the aging population and the increasing proportion of residents, the national medical expenditure is increasing, which belongs to the rigid demand; At the same time, with the continuous improvement of people's health standards and the development of internet medical technology, the big health industry will continue to grow for a long time. According to the data, the revenue of China's big health industry will exceed 7 trillion yuan in 2020, and it is expected to reach 8 trillion yuan in 2021, an increase of 8.1%. Among them, thanks to the development of big health industry and the growth of pharmaceutical demand during the epidemic period, biopharmaceuticals and medical devices have performed well, becoming China's new economy industry with high investment enthusiasm in 2020, with investment projects of 91.9 billion yuan and 27.3 billion yuan respectively. -
艾媒咨询|2021全球与中国医药电商市场与发展趋势研究报告
本报告研究涉及企业/品牌/案例：阿里健康，美团，京东健康，叮当快药，1药网，Walgreens，百度健康，药材买卖网，中药材天地网，找药网，九州通，药易购，珍诚医药在线，CVS
在政策利好、互联网技术等多重因素推动下，中国医药电商行业规模持续快速发展，2020年中国医药电商市场交易规模达到1956亿元。当前，中药电商商业模式主要为B2B、B2C、O2O与DTP四种类型，其中，2020年，医药电商B2C模式占比近6%，市场规模为116亿元；医药电商B2C模式占比近84%，市场规模为1640亿元，成为当前的主流。此外，近几年兴起的O2O模式，主要通过“引流-转化-消费-反馈”等实现盈利，而DTP药房模式下，患者在医院开取处方后，药房根据处方以患者或家属指定的时间和地点送药上门，被称为高值新特药直送平台。
Driven by favorable policies, Internet technology and other factors, the scale of China's pharmaceutical e-commerce industry continues to develop rapidly, with the transaction scale of China's pharmaceutical e-commerce market reaching 1956 billion yuan in 2020. At present, the business models of traditional Chinese medicine e-commerce are mainly B2B, B2C, o2o and DTP. In 2020, the B2C model of pharmaceutical e-commerce accounts for nearly 6% and the market scale is 11.6 billion yuan; the B2C model of pharmaceutical e-commerce accounts for nearly 84% and the market scale is 164 billion yuan, which has become the current mainstream. In addition, the o2o mode, which has sprung up in recent years, mainly achieves profits through "drainage transformation consumption feedback". In the DTP pharmacy mode, after patients get prescriptions in the hospital, the pharmacy delivers drugs to the door at the time and place designated by the patients or their families according to the prescriptions, which is known as the high value new special drugs direct delivery platform. -
艾媒咨询|2020年中国新经济独角兽&准独角兽TOP200榜单解读及标杆企业研究报告
本报告研究涉及企业/品牌/案例：丁香园、叮当快药、字节跳动、小象大鹅、小红书、豌豆公主、阿里云、蜜蜂科技-BEEPLUS、盒马网络、回收宝、商汤科技、珞石科技、猿辅导、编程猫。
在产业数字化及居民消费升级的推动下，新经济产业蓬勃发展，培育出多家独角兽及准独角兽企业。在2020年中国新经济独角兽及准独角兽两百强榜单中，分别有39.5%和42.0%的独角兽及准独角兽企业分布在华东地区，并有71.0%及75.0%的独角兽及准独角兽企业分布在北上广，体现出北上广作为超一线城市在培育独角兽企业上具有明显优势。iiMedia Research(艾媒咨询)数据显示，在两百强名单中，企业服务领域分布了20家独角兽企业及49家准独角兽企业，体现出在新经济发展环境下，各类崭新的商业模式和领域被挖掘，同时也存在更多市场主体对企业服务存在需求，也推动更多企业服务企业跻身独角兽/准独角兽行列。
Driven by the industrial digitalization and increasing consuming power, the new economy industry is growing rapidly, and cultivated lots of unicorn and quasi unicorn enterprises. In the 2020 China New Economy Unicorn and Quasi Unicorn Enterprise Top200 List, 39.5% and 42.0% of the unicorn and quasi unicorn enterprises are located in the eastern China respectively, while 71.0% and 75.0% are located in Beijing, Shanghai and Guangzhou, which showed that as super tier one cities, Beijing, Shanghai and Guangzhou have the clear advantage in terms of cultivating unicorn enterprises. As the data of iiMedia Research showed, within the Top200 list, there are 20 unicorn enterprises and 49 quasi unicorn enterprises in the field of enterprise service, which showed that under the growth of new economy, new types of business models and fields are discovered, and there are more market entities that have demand on enterprise services, which pushed more enterprise service enterprises into the ranks of unicorn/quasi unicorn. -
艾媒咨询|2020年中国细胞生物产业和商业应用分析报告
本报告研究涉及企业/品牌/案例：华夏源、复星医药。
中国细胞生物产业类型呈现多样化趋势，细胞生物临床研究不断深化，伴随生态合作的拓展将进一步加速细胞生物产业生态圈的形成，生态圈的完善将在很大限度上推动产业快速发展。数据显示，中国细胞治疗企业融资金额不断增加，从2014年的0.2亿元增长至2019年的28.9亿元。其中，2018年中国细胞治疗企业融资额同比增长706.8%，呈现迅猛发展态势。未来中国细胞生物产业的发展将充满机遇，同时也有挑战并存。后续产业的发展，将在5G、人工智能等新技术应用下加速升级。面临多端变化的市场格局，企业也应积极开展生态合作以及更为密切关注市场需求动向，将疗法和新一代医疗创新技术深度融合，实现市场产品多元化与差异化，并推出独特性的精准治疗，从而最大限度地释放产业价值。
The types of cell biological industry in China show a trend of diversification, and the deepening of cell biological clinical research will further accelerate the formation of the cell biological industry ecosystem with the expansion of ecological cooperation, and the improvement of the ecosystem will promote the rapid development of the industry to a large extent. Data show that the financing amount of Chinese cell therapy enterprises keeps increasing, from 20 million yuan in 2014 to 2.89 billion yuan in 2019. Among them, in 2018, the financing amount of Chinese cell therapy enterprises increased by 706.8% year on year, showing a rapid development trend. In the future, the development of China's cell biology industry will be full of opportunities and challenges. The development of subsequent industries will be accelerated with the application of new technologies such as 5G and ARTIFICIAL intelligence. In the face of the changing market pattern, enterprises should also actively carry out ecological cooperation and pay close attention to the trend of market demand, deeply integrate therapy and new-generation medical innovation technology, realize the diversification and differentiation of market products, and launch unique precision therapy, so as to maximize the release of industrial value.
- 1
- 2
- 3
- 4
